Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
62.76
+20.82 (49.64%)
At close: Mar 9, 2026, 4:00 PM EDT
62.45
-0.31 (-0.49%)
After-hours: Mar 9, 2026, 7:59 PM EDT

Xenon Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-345.91-234.33-182.39-125.37-78.88
Upgrade
Depreciation & Amortization
2.542.562.061.410.91
Upgrade
Loss (Gain) From Sale of Investments
0.63--3.552.930.72
Upgrade
Stock-Based Compensation
53.7150.7232.3720.3810.02
Upgrade
Other Operating Activities
5.56-6.05-5.50.910.39
Upgrade
Change in Accounts Receivable
0.1-0.610.131.76-0.46
Upgrade
Change in Accounts Payable
5.518.533.938.062.97
Upgrade
Change in Unearned Revenue
-----3.64
Upgrade
Change in Other Net Operating Assets
-1.26-2.21.84-11.1-1.52
Upgrade
Operating Cash Flow
-279.12-181.39-151.11-101.03-69.5
Upgrade
Capital Expenditures
-0.8-3.08-5.62-2.89-2.05
Upgrade
Investment in Securities
218.8168.08-105.77-290.51-244.72
Upgrade
Investing Cash Flow
218165-111.39-293.41-246.77
Upgrade
Issuance of Common Stock
117.1112.13353.52278.47447.54
Upgrade
Financing Cash Flow
117.1112.13353.52278.47447.54
Upgrade
Foreign Exchange Rate Adjustments
0.46-1.670.38-2.48-0.59
Upgrade
Net Cash Flow
56.45-5.9391.4-118.45130.68
Upgrade
Free Cash Flow
-279.92-184.46-156.73-103.92-71.55
Upgrade
Free Cash Flow Margin
-3732.23%---1101.57%-388.09%
Upgrade
Free Cash Flow Per Share
-3.53-2.37-2.34-1.72-1.64
Upgrade
Levered Free Cash Flow
-175.08-117.59-99.88-54.3-43.76
Upgrade
Unlevered Free Cash Flow
-175.08-117.59-99.88-54.3-43.76
Upgrade
Change in Working Capital
4.365.715.9-1.28-2.65
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.